BNTC compared with CTNM: revenue, margins and what each company keeps, and the suppliers and customers both name

BNTCBenitec Biopharma Inc.

Mkt capRevenueRevenue

CTNMContineum Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

BNTCBenitec Biopharma Inc.

CTNMContineum Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BNTC

0 of 4at or beyond implied

Reportimpliedrealized× implied

Sep 15 '26±33.9%▼−8.53%×0.25

Q3 FY26±46.8%▲+1.72%×0.04

Feb 12 '26±42.4%▼−2.66%×0.06

Nov 17 '25±33.2%▲+2.81%×0.08

CTNM1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−1.65%—

= impliedBNTC realized, solidCTNM realized, hatchedOne scale, both sides: full bar = 47%× = |realized| ÷ impliedSource: market data

BNTCBenitec Biopharma Inc.

8.66▲+1.94%

Mkt cap$304.9MRevenue$7,000Q4 FY23

CTNMContineum Therapeutics, Inc.

9.83▲+2.78%

Regular sessionNov 3 '26

Mkt cap$359.7MRevenue—

Compare

Regular sessionNov 3 '26

BNTCBenitec Biopharma Inc.

CTNMContineum Therapeutics, Inc.

8.66▲+1.94%

Price

9.83▲+2.78%

$304.9M

Mkt cap

$359.7M

Q4 FY23$7,000

Revenue

—

BNTC8.66▲+1.94%vsCTNM9.83▲+2.78%Regular sessionNov 3 '26